JP2009536196A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009536196A5 JP2009536196A5 JP2009509485A JP2009509485A JP2009536196A5 JP 2009536196 A5 JP2009536196 A5 JP 2009536196A5 JP 2009509485 A JP2009509485 A JP 2009509485A JP 2009509485 A JP2009509485 A JP 2009509485A JP 2009536196 A5 JP2009536196 A5 JP 2009536196A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- formula
- phenyl
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 125000001153 fluoro group Chemical group F* 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- -1 C 1 -C 6 alkoxy Chemical group 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000005842 heteroatom Chemical group 0.000 claims 7
- 239000001301 oxygen Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 229910052717 sulfur Chemical group 0.000 claims 6
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 4
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 4
- 208000027418 Wounds and injury Diseases 0.000 claims 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 206010006451 bronchitis Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 239000011593 sulfur Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 2
- 108010028275 Leukocyte Elastase Proteins 0.000 claims 2
- 102000016799 Leukocyte elastase Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000008469 Peptic Ulcer Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 201000009267 bronchiectasis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 208000007451 chronic bronchitis Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000011906 peptic ulcer disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- XMJYJGDTXWJZOJ-UHFFFAOYSA-N 1-(3-chloro-4-fluorophenyl)-5-[2-(4-cyanophenyl)pyrazol-3-yl]-n,6-dimethyl-2-oxopyridine-3-carboxamide Chemical compound CC=1N(C=2C=C(Cl)C(F)=CC=2)C(=O)C(C(=O)NC)=CC=1C1=CC=NN1C1=CC=C(C#N)C=C1 XMJYJGDTXWJZOJ-UHFFFAOYSA-N 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- XTMYKZUDOSTQFY-UHFFFAOYSA-N 5-[2-(4-chlorophenyl)pyrazol-3-yl]-n,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound CC=1N(C=2C=C(C=CC=2)C(F)(F)F)C(=O)C(C(=O)NC)=CC=1C1=CC=NN1C1=CC=C(Cl)C=C1 XTMYKZUDOSTQFY-UHFFFAOYSA-N 0.000 claims 1
- QZVIXMNTGHGVEI-UHFFFAOYSA-N 5-[2-(4-cyanophenyl)-1,2,4-triazol-3-yl]-n,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound CC=1N(C=2C=C(C=CC=2)C(F)(F)F)C(=O)C(C(=O)NC)=CC=1C1=NC=NN1C1=CC=C(C#N)C=C1 QZVIXMNTGHGVEI-UHFFFAOYSA-N 0.000 claims 1
- KIMZBWYHGGXELV-UHFFFAOYSA-N 5-[2-(4-cyanophenyl)pyrazol-3-yl]-6-methyl-n-[(4-methylsulfonylphenyl)methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound O=C1N(C=2C=C(C=CC=2)C(F)(F)F)C(C)=C(C=2N(N=CC=2)C=2C=CC(=CC=2)C#N)C=C1C(=O)NCC1=CC=C(S(C)(=O)=O)C=C1 KIMZBWYHGGXELV-UHFFFAOYSA-N 0.000 claims 1
- IVORQAQKBHVZHS-UHFFFAOYSA-N 5-[2-(4-cyanophenyl)pyrazol-3-yl]-n,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound CC=1N(C=2C=C(C=CC=2)C(F)(F)F)C(=O)C(C(=O)NC)=CC=1C1=CC=NN1C1=CC=C(C#N)C=C1 IVORQAQKBHVZHS-UHFFFAOYSA-N 0.000 claims 1
- ATCWZNNQWJCJKS-UHFFFAOYSA-N 5-[2-(4-fluorophenyl)pyrazol-3-yl]-n,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound CC=1N(C=2C=C(C=CC=2)C(F)(F)F)C(=O)C(C(=O)NC)=CC=1C1=CC=NN1C1=CC=C(F)C=C1 ATCWZNNQWJCJKS-UHFFFAOYSA-N 0.000 claims 1
- ALLZACDKHLHGPV-UHFFFAOYSA-N 5-[2-amino-5-(4-chlorophenyl)-1,3-thiazol-4-yl]-n,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound CC=1N(C=2C=C(C=CC=2)C(F)(F)F)C(=O)C(C(=O)NC)=CC=1C=1N=C(N)SC=1C1=CC=C(Cl)C=C1 ALLZACDKHLHGPV-UHFFFAOYSA-N 0.000 claims 1
- QFKFSRSXKCLKOE-UHFFFAOYSA-N 5-[2-amino-5-(4-cyanophenyl)-1,3-thiazol-4-yl]-n,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound CC=1N(C=2C=C(C=CC=2)C(F)(F)F)C(=O)C(C(=O)NC)=CC=1C=1N=C(N)SC=1C1=CC=C(C#N)C=C1 QFKFSRSXKCLKOE-UHFFFAOYSA-N 0.000 claims 1
- JBDNBHUJCALBPG-UHFFFAOYSA-N 5-[3-(4-cyanophenyl)triazol-4-yl]-n,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound CC=1N(C=2C=C(C=CC=2)C(F)(F)F)C(=O)C(C(=O)NC)=CC=1C1=CN=NN1C1=CC=C(C#N)C=C1 JBDNBHUJCALBPG-UHFFFAOYSA-N 0.000 claims 1
- VMYAMXXMGCFFCI-UHFFFAOYSA-N 5-[4-(4-chlorophenyl)-1,3-oxazol-5-yl]-n,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound CC=1N(C=2C=C(C=CC=2)C(F)(F)F)C(=O)C(C(=O)NC)=CC=1C=1OC=NC=1C1=CC=C(Cl)C=C1 VMYAMXXMGCFFCI-UHFFFAOYSA-N 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000012038 nucleophile Substances 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79878606P | 2006-05-08 | 2006-05-08 | |
| PCT/SE2007/000441 WO2007129962A1 (en) | 2006-05-08 | 2007-05-07 | 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009536196A JP2009536196A (ja) | 2009-10-08 |
| JP2009536196A5 true JP2009536196A5 (https=) | 2010-06-03 |
Family
ID=38667997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009509485A Withdrawn JP2009536196A (ja) | 2006-05-08 | 2007-05-07 | 好中球エラスターゼ活性の阻害が有益である疾患または状態の処置のための２−ピリドン誘導体 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7998984B2 (https=) |
| EP (1) | EP2018375B1 (https=) |
| JP (1) | JP2009536196A (https=) |
| KR (1) | KR20090017573A (https=) |
| CN (1) | CN101490033A (https=) |
| AR (1) | AR060875A1 (https=) |
| AT (1) | ATE459615T1 (https=) |
| AU (1) | AU2007248950B2 (https=) |
| BR (1) | BRPI0711357A2 (https=) |
| CA (1) | CA2649813A1 (https=) |
| CL (1) | CL2007001282A1 (https=) |
| DE (1) | DE602007005120D1 (https=) |
| ES (1) | ES2339607T3 (https=) |
| IL (1) | IL194948A0 (https=) |
| MX (1) | MX2008013836A (https=) |
| NO (1) | NO20084872L (https=) |
| TW (1) | TW200808763A (https=) |
| UY (1) | UY30328A1 (https=) |
| WO (1) | WO2007129962A1 (https=) |
| ZA (1) | ZA200809024B (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0302486D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| TW200808771A (en) * | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds II |
| TW200808763A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds I |
| PL2066662T3 (pl) * | 2006-09-21 | 2013-05-31 | Kyorin Seiyaku Kk | Inhibitory hydrolaz serynowych |
| DE102007031397A1 (de) * | 2007-07-05 | 2009-01-08 | D2O Bioscience Group Ltd. | Verwendung von Deuteriumoxid zur Behandlung von Virus-basierten Erkrankungen der Haut |
| WO2009061271A1 (en) | 2007-11-06 | 2009-05-14 | Astrazeneca Ab | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase |
| EP2508189A3 (de) * | 2008-04-20 | 2012-11-07 | D2 Bioscience Group Ltd | Verwendung von Deuteriumoxid als Elastase-Inhibitor |
| DE102009003942A1 (de) * | 2009-01-07 | 2010-07-08 | D2O Biosience Group Ltd., Hamilton | Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges |
| TW201036957A (en) * | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
| SG176571A1 (en) * | 2009-05-19 | 2012-01-30 | Vivia Biotech Sl | Methods for providing personalized medicine tests ex vivo for hematological neoplasms |
| CA2773618A1 (en) * | 2009-10-02 | 2011-04-07 | Astrazeneca Ab | 2-pyridone compounds used as inhibitors of neutrophil elastase |
| DE102010030187A1 (de) | 2010-06-16 | 2011-12-22 | Bayer Schering Pharma Aktiengesellschaft | 4-Cyan-2-sulfonylphenyl)pyrazolyl-substituierte Pyridinone und Pyrazinone und ihre Verwendung |
| JP2013177318A (ja) * | 2010-06-30 | 2013-09-09 | Dainippon Sumitomo Pharma Co Ltd | ジヒドロピリミジノン誘導体およびその医薬用途 |
| CN104024241B (zh) | 2011-08-01 | 2016-01-20 | 大日本住友制药株式会社 | 尿嘧啶衍生物和其用于医学目的的用途 |
| US9102624B2 (en) | 2012-08-23 | 2015-08-11 | Boehringer Ingelheim International Gmbh | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
| US20140057926A1 (en) | 2012-08-23 | 2014-02-27 | Boehringer Ingelheim International Gmbh | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
| US20140057920A1 (en) | 2012-08-23 | 2014-02-27 | Boehringer Ingelheim International Gmbh | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
| US9409870B2 (en) * | 2014-12-15 | 2016-08-09 | Chiesi Farmaceutici S.P.A. | Compounds |
| HK1249504A1 (zh) | 2015-09-02 | 2018-11-02 | Glaxosmithkline Intellectual Property (No. 2) Limited | 用作溴结构域抑制剂的吡啶酮二甲酰胺 |
| CN106674098B (zh) * | 2016-12-23 | 2019-07-02 | 中国医科大学 | N-(3-氰基-4-烷氧基苯基)吡啶甲酰胺类化合物及其用途 |
| EP3749697A4 (en) | 2018-02-05 | 2021-11-03 | Bio-Rad Laboratories, Inc. | CHROMATOGRAPHY RESIN WITH LIGAND MIXED MODE ANIONIC / HYDROPHOBIC EXCHANGE |
| CN114650819A (zh) | 2019-09-17 | 2022-06-21 | 美莱奥生物制药第四有限公司 | 用于治疗移植物排斥、闭塞性细支气管炎综合征和移植物抗宿主病的阿维来司他 |
| WO2021209740A1 (en) | 2020-04-16 | 2021-10-21 | Mereo Biopharma 4 Limited | Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection |
| EP4419102A1 (en) | 2021-10-20 | 2024-08-28 | Mereo Biopharma 4 Limited | Neutrophil elastase inhibitors for use in the treatment of fibrosis |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2358891A1 (fr) * | 1976-07-22 | 1978-02-17 | Yamanouchi Pharma Co Ltd | Composes heterocycliques contenant un azote, utilise comme agents analgesiques et anti-inflammatoires |
| DE2706977A1 (de) * | 1977-02-18 | 1978-08-24 | Hoechst Ag | Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung |
| EP0008864A1 (en) | 1978-08-15 | 1980-03-19 | FISONS plc | Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them |
| JPH02152966A (ja) | 1988-12-05 | 1990-06-12 | Otsuka Pharmaceut Co Ltd | ４−ヒドロキシカルボスチリル誘導体 |
| US5521179A (en) * | 1991-04-18 | 1996-05-28 | Zeneca Limited | Heterocyclic amides |
| US5441960A (en) * | 1992-04-16 | 1995-08-15 | Zeneca Limited | 1-pyrimidinylacetamide human leukocyte elastate inhibitors |
| IL130181A0 (en) | 1996-12-05 | 2000-06-01 | Amgen Inc | Substituted pyrimidone and pyridone compounds and methods of use |
| JPH1171351A (ja) * | 1997-08-29 | 1999-03-16 | Ss Pharmaceut Co Ltd | 置換キノロン誘導体及びこれを含有する医薬 |
| IL152848A0 (en) | 2000-06-12 | 2003-06-24 | Eisai Co Ltd | 1,2-dihydropyridine derivatives, pharmaceutical compositions containing the same and methods for the production thereof |
| ES2330719T3 (es) * | 2000-12-28 | 2009-12-15 | SHIONOGI & CO., LTD. | Derivados de 2-piridona con afinidad para el receptor cannabinoide de tipo 2. |
| BR0211900A (pt) * | 2001-08-14 | 2004-08-24 | Toyama Chemical Co Ltd | Método para inibição do desenvolvimento de vìrus e/ou virucida, análogos de nucleotìdeo de pirazina e de nucleosìdeo de pirazina, precursor do inibidor da polimerase de rna, inibidor da polimerase de rna, método para tratar pacientes infectados por vìrus, e, usos de um análogo de nucleotìdeo de pirazina ou um sal deste e de um análogo de nucleosìdeo de pirazina ou um sal deste |
| GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| GB2383326A (en) | 2001-12-20 | 2003-06-25 | Bayer Ag | Antiinflammatory dihydropyridines |
| MXPA03000145A (es) * | 2002-01-07 | 2003-07-15 | Pfizer | Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4. |
| PT1477186E (pt) * | 2002-02-19 | 2010-02-11 | Shionogi & Co | Antipruriginosos |
| JP4619122B2 (ja) | 2002-08-27 | 2011-01-26 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | Ｈｎｅインヒビターとしてのジヒドロピリジノン誘導体 |
| GB2392910A (en) | 2002-09-10 | 2004-03-17 | Bayer Ag | 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors |
| TW200500341A (en) | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
| SE0302324D0 (sv) * | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
| SE0302323D0 (sv) | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
| SE0302486D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| JP5134248B2 (ja) | 2004-02-19 | 2013-01-30 | バイエル・ファルマ・アクチェンゲゼルシャフト | ジヒドロピリジノン誘導体 |
| CA2557271C (en) | 2004-02-26 | 2012-08-21 | Bayer Healthcare Ag | 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors |
| US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| KR200365249Y1 (ko) * | 2004-07-28 | 2004-10-21 | 추윤정 | 전동 퍼프 |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
| TW200700392A (en) | 2005-03-16 | 2007-01-01 | Astrazeneca Ab | Novel compounds |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| GB0512940D0 (en) | 2005-06-24 | 2005-08-03 | Argenta Discovery Ltd | Compounds and their use |
| GB0605469D0 (en) | 2006-03-17 | 2006-04-26 | Argenta Discovery Ltd | Multimers of heterocyclic compounds and their use |
| NZ572250A (en) | 2006-05-04 | 2011-10-28 | Pulmagen Therapeutics Inflammation Ltd | Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors |
| TW200808771A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds II |
| TW200808763A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds I |
| US20110003858A1 (en) | 2006-09-04 | 2011-01-06 | Bergstroem Lena | Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors |
| WO2008104752A1 (en) | 2007-02-26 | 2008-09-04 | Astrazeneca Ab | Dihydropyridones as elastase inhibitors |
| WO2009058076A1 (en) | 2007-11-02 | 2009-05-07 | Astrazeneca Ab | 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase |
| WO2009061271A1 (en) | 2007-11-06 | 2009-05-14 | Astrazeneca Ab | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase |
| TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
-
2007
- 2007-04-27 TW TW096115047A patent/TW200808763A/zh unknown
- 2007-05-07 CA CA002649813A patent/CA2649813A1/en not_active Abandoned
- 2007-05-07 MX MX2008013836A patent/MX2008013836A/es active IP Right Grant
- 2007-05-07 ES ES07748105T patent/ES2339607T3/es active Active
- 2007-05-07 AU AU2007248950A patent/AU2007248950B2/en not_active Ceased
- 2007-05-07 BR BRPI0711357-9A patent/BRPI0711357A2/pt not_active IP Right Cessation
- 2007-05-07 US US12/299,879 patent/US7998984B2/en not_active Expired - Fee Related
- 2007-05-07 EP EP07748105A patent/EP2018375B1/en active Active
- 2007-05-07 WO PCT/SE2007/000441 patent/WO2007129962A1/en not_active Ceased
- 2007-05-07 DE DE602007005120T patent/DE602007005120D1/de active Active
- 2007-05-07 UY UY30328A patent/UY30328A1/es not_active Application Discontinuation
- 2007-05-07 CN CNA2007800259071A patent/CN101490033A/zh active Pending
- 2007-05-07 CL CL2007001282A patent/CL2007001282A1/es unknown
- 2007-05-07 KR KR1020087029811A patent/KR20090017573A/ko not_active Ceased
- 2007-05-07 AT AT07748105T patent/ATE459615T1/de not_active IP Right Cessation
- 2007-05-07 JP JP2009509485A patent/JP2009536196A/ja not_active Withdrawn
- 2007-05-08 AR ARP070101994A patent/AR060875A1/es unknown
-
2008
- 2008-10-21 ZA ZA200809024A patent/ZA200809024B/xx unknown
- 2008-10-27 IL IL194948A patent/IL194948A0/en unknown
- 2008-11-19 NO NO20084872A patent/NO20084872L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009536196A5 (https=) | ||
| JP2009536197A5 (https=) | ||
| RU2008143457A (ru) | Производные-2-пиразинона для лечения заболевания или состояния, при которых полезно ингибирование активности нейтрофильной эластазы | |
| JP2010533158A5 (https=) | ||
| ES2327940T3 (es) | 3-(4-heterociclil-1,2,3-triazol-1-il)-n-aril-benzamidas en calidad de inhibidores de la produccion de citocinas para el tratamiento de enfermedades inflamatorias cronicas. | |
| JP2011502982A5 (https=) | ||
| JP2015517580A5 (https=) | ||
| JP2007523182A5 (https=) | ||
| JP2009534386A5 (https=) | ||
| JP2018118992A5 (https=) | ||
| JP2010513444A5 (https=) | ||
| AR072201A1 (es) | 2-arilaminoquinazolinas para el tratamiento de enfermedades proliferativas | |
| JP2015533157A5 (https=) | ||
| JP2020527588A5 (https=) | ||
| JP2021501220A5 (https=) | ||
| JP2009533427A5 (https=) | ||
| JP2014518214A5 (https=) | ||
| RU2007101236A (ru) | Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей | |
| IL258577A (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| JP2010502615A5 (https=) | ||
| JP2014525444A5 (https=) | ||
| JP2016513660A5 (https=) | ||
| JP2005508967A5 (https=) | ||
| JP2018535999A5 (https=) | ||
| JP2019503385A5 (https=) |